GLENMARK PHARMA: Q1 CONS PBT 6.43B RUPEES VS 4.2B (YOY)

 31 Jul 2026 06:50 PM

GLENMARK PHARMA: Q1 CONS PBT 6.43B RUPEES VS 4.2B (YOY)

GLENMARK PHARMA: Q1 CONS NET PROFIT 4.83B RUPEES VS 469M (YOY)

 31 Jul 2026 06:51 PM

GLENMARK PHARMA: Q1 CONS NET PROFIT 4.83B RUPEES VS 469M (YOY)

GLENMARK PHARMA: Q1 REVENUE 40.2B RUPEES VS 32.6B (YOY)

 31 Jul 2026 06:51 PM

GLENMARK PHARMA: Q1 REVENUE 40.2B RUPEES VS 32.6B (YOY)

GLENMARK PHARMA: Q1 EBITDA 7.84B RUPEES VS 5.8B (YOY) || Q1 EBITDA MARGIN 19.51% VS 17.78% (YOY)

 31 Jul 2026 06:51 PM

GLENMARK PHARMA: Q1 EBITDA 7.84B RUPEES VS 5.8B (YOY) || Q1 EBITDA MARGIN 19.51% VS 17.78% (YOY)

Glenmark Pharma: Glenmark Pharmaceuticals Inc. USA Introduces Generic Sugammadex Injection In A $1.6 Billion Annual Market Opportunity

 29 Jul 2026 07:54 AM

Glenmark Pharma: Glenmark Pharmaceuticals Inc. USA Introduces Generic Sugammadex Injection In A $1.6 Billion Annual Market Opportunity

Glenmark Pharma: Expects 70% Of Revenue From Innovative Drugs In 5-6 Years, Highlighting Shift To Innovation-Based Business Model. - ET

 22 Jul 2026 09:04 AM

Glenmark Pharma: Expects 70% Of Revenue From Innovative Drugs In 5-6 Years, Highlighting Shift To Innovation-Based Business Model. - ET

Glenmark Pharmaceuticals: Will Hold Its Q1 Earnings Call On August 3 At 8:30 AM.

 21 Jul 2026 05:33 PM

Glenmark Pharmaceuticals: Will Hold Its Q1 Earnings Call On August 3 At 8:30 AM.

Glenmark Pharma: Co. Gets U.S. FDA Approval to Allow Ryaltris Nasal Spray for Kids Aged 6 to Under 12 Years

 21 Jul 2026 08:53 AM

Glenmark Pharma: Co. Gets U.S. FDA Approval to Allow Ryaltris Nasal Spray for Kids Aged 6 to Under 12 Years

Glenmark Pharma: Glenmark Pharmaceuticals Inc., USA Introduces Olanzapine Injection With Annual U.S. Sales Around $25.4 Million

 06 Jul 2026 09:01 AM

Glenmark Pharma: Glenmark Pharmaceuticals Inc., USA Introduces Olanzapine Injection With Annual U.S. Sales Around $25.4 Million

Glenmark Pharma: Co's Trastuzumab Rezetecan Trial for Platinum-Resistant Ovarian Cancer Gets Phase 3 Approval in India, First Among Licensed Markets.

 02 Jul 2026 08:42 AM

Glenmark Pharma: Co's Trastuzumab Rezetecan Trial for Platinum-Resistant Ovarian Cancer Gets Phase 3 Approval in India, First Among Licensed Markets.

Glenmark Pharmaceuticals: Launches Methylene Blue Injection USP In The USA, Available In 50 MG/10 ML Single-Dose Vial; Product Matches Provayblue® Injection; Provayblue® Market Reached About $19 Million In Annual Sales.

 17 Jun 2026 08:51 AM

Glenmark Pharmaceuticals: Launches Methylene Blue Injection USP In The USA, Available In 50 MG/10 ML Single-Dose Vial; Product Matches Provayblue® Injection; Provayblue® Market Reached About $19 Million In Annual Sales.

Glenmark Pharmaceuticals: Launches Winlevi® Cream For Acne Treatment In Major European Markets; First New Chemical Entity Launch In Europe; Enhances Dermatology Product Range With Direct Market Entries.

 11 Jun 2026 10:22 AM

Glenmark Pharmaceuticals: Launches Winlevi® Cream For Acne Treatment In Major European Markets; First New Chemical Entity Launch In Europe; Enhances Dermatology Product Range With Direct Market Entries.

Glenmark Pharmaceuticals: Investec maintains a Buy on Glenmark Pharmaceuticals with a Target Price of ₹2,750, citing confidence in 13–15% sales growth and 100bps margin expansion to FY30, strong growth in India and the US, innovation-led products contributing 30% of sales by FY30, and optionality from its innovation arm IGI following the AbbVie deal and planned annual IND filings from FY27.

 11 Jun 2026 08:59 AM

Glenmark Pharmaceuticals: Investec maintains a Buy on Glenmark Pharmaceuticals with a Target Price of ₹2,750, citing confidence in 13–15% sales growth and 100bps margin expansion to FY30, strong growth in India and the US, innovation-led products contributing 30% of sales by FY30, and optionality from its innovation arm IGI following the AbbVie deal and planned annual IND filings from FY27.

Glenmark: Company Aims For 13-15% Revenue Growth, Targets 23% EBITDA Margin By FY27, Focuses On Margin Growth And Strong Returns. Company Looks For Over 23% ROCE And 20%+ ROE While Keeping A Net Cash Position.

 09 Jun 2026 05:02 PM

Glenmark: Company Aims For 13-15% Revenue Growth, Targets 23% EBITDA Margin By FY27, Focuses On Margin Growth And Strong Returns. Company Looks For Over 23% ROCE And 20%+ ROE While Keeping A Net Cash Position.

Glenmark: Company Plans One IND Filing Each Year; Aims for Average Annual Investment of About $70 Million.

 09 Jun 2026 04:58 PM

Glenmark: Company Plans One IND Filing Each Year; Aims for Average Annual Investment of About $70 Million.

Glenmark Pharmaceuticals Limited: Aims To Grow Its Respiratory Products In FY27; Winlevi® Has Gained EU Approval With A Launch Planned For FY27, And Aumolertinib's Initial Launch Is Anticipated In H2 FY27.

 30 May 2026 03:07 PM

Glenmark Pharmaceuticals Limited: Aims To Grow Its Respiratory Products In FY27; Winlevi® Has Gained EU Approval With A Launch Planned For FY27, And Aumolertinib's Initial Launch Is Anticipated In H2 FY27.

GLENMARK PHARMA: Q4 CONS NET PROFIT 3B RUPEES VS 465M (YOY) || Q4 REVENUE 37.6B RUPEES VS 32.6B (YOY)

 29 May 2026 08:25 PM

GLENMARK PHARMA: Q4 CONS NET PROFIT 3B RUPEES VS 465M (YOY) || Q4 REVENUE 37.6B RUPEES VS 32.6B (YOY)

GLENMARK PHARMA: Q4 EBITDA 9.4B RUPEES VS 5.6B (YOY) || Q4 EBITDA MARGIN 25% VS 17.23% (YOY)

 29 May 2026 08:25 PM

GLENMARK PHARMA: Q4 EBITDA 9.4B RUPEES VS 5.6B (YOY) || Q4 EBITDA MARGIN 25% VS 17.23% (YOY)

Glenmark Pharma: Joint Venture IGI Introduces ISB 2301, A Novel Immune Cell Activator For Treating Various Solid Tumors.

 20 May 2026 04:25 PM

Glenmark Pharma: Joint Venture IGI Introduces ISB 2301, A Novel Immune Cell Activator For Treating Various Solid Tumors.

Glenmark Pharmaceuticals: Introduces Vancomycin Hydrochloride Injection In 500 MG And 1 G Vials In The U.S.; Product Matches Fresenius Kabi's Drug; Market Sales Hit $37.9 Million.

 18 May 2026 09:04 AM

Glenmark Pharmaceuticals: Introduces Vancomycin Hydrochloride Injection In 500 MG And 1 G Vials In The U.S.; Product Matches Fresenius Kabi's Drug; Market Sales Hit $37.9 Million.